In a peer-reviewed study published May 17 in PLOS Medicine, scientists found that mRNA-based COVID-19 vaccines were superior to adenovirus vector-based ones across major variants of the SARS-CoV-2 virus.
Janssen terminated a seven-year-old vaccine collaboration with Bavarian Nordic. The two companies partnered in 2015 to develop potential vaccines against the hepatitis B virus and human papillomaviruses.
COVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months.
The Janssen COVID-19 vaccine is now limited to certain individuals ages 18 and up after the U.S. Food and Drug Administration downgraded its emergency use authorization.
Apr 08, 2022 By Jazmine Colatriano, M.S. BioSpace Johnson & Johnson’s Janssen Pharmaceutical secured an arbitrary win regarding royalty decisions stemming from the licensing and marketing of daratumumab, an anti-CD38 monoclonal antibody treatment that has multiple indications approved by the U.S. Food and Drug Administration (FDA). The confidential arbitration was conducted by a tribunal of three earlier this […]
The Digital Medicine Society (DiMe), in partnership with Anthem, Biogen, Eli Lilly, Evidation, Janssen, Merck, Pfizer and Savvy Co-op, announced the public launch of the 3Ps of Digital Endpoint Value (3Ps), a toolkit of resources created to facilitate the inclusion of digital endpoints as evidence for payers in reimbursement decisions for new drugs.
ViiV Healthcare and Janssen Pharmaceutical’s Cabenuva treatment for people living with human immunodeficiency virus (HIV-1) received a label update as adult patients now have the option to start the injectable regimen without the need for an oral lead-in period first.
An experimental oral drug being developed by Redhill Biopharma Inc. interrupts a process that helps the coronavirus infect cells and might keep COVID-19 patients from becoming seriously ill, the company said. Additionally, the risk of hospitalization after vaccination with Johnson & Johnson’s COVID-19 vaccine was about five times higher than for those who received the Pfizer and BioNTech shot, a large French study found.
RNA-focused Remix Therapeutics agreed on a strategic small-molecule discovery and development collaboration with Janssen Pharmaceutica N.V., a division of Johnson & Johnson.
EVERSANA, the pioneer of next generation commercial services to the global life sciences industry, and THREAD, a leading technology and service provider enabling electronic clinical outcome assessments (eCOAs) and decentralized clinical trials (DCTs), announced a new combined offering to give pharmaceutical companies a comprehensive and simultaneous view of clinical research participants, followed by data and detailed analysis across the care continuum.